EMCC European Monitoring Centre on Change

Teva

Company/Organisation:
Teva

Geographic Location

Country: Ireland
Region: Dublin; Southern and Eastern

Company

Sector: Manufacturing
Manufacture of pharmaceuticals, medicinal chemical and botanical products
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
Number Employed: 110

Employment Effects

Announcement Date: 07-05-2021
Planned Job Reductions min: 110
Type of Restructuring: Offshoring/Delocalisation
Employment Effect Start: 01-10-2022
Foreseen End Date: 01-01-2023
Direct Dismissals: 110

Additional Information

Pharmaceutical company Teva will close a manufacturing plant in Dublin from the third quarter of 2022. The closure is scheduled to be completed by January of 2023 and will result in the loss of 110 jobs.

Production at the plant, which manufactures nappy rash cream Sudocrem is to move to Bulgaria.

The senior director of corporate affairs for Teva UK and Ireland said that the Baldoyle plant does not have the capacity to grow any further and as part of global consolidation plans it has decided to move production to an existing plant in Bulgaria.

For previous restructuring event related to Teva in Ireland, see Teva-IE-2009

Sources: